# Galaxy Gaming, Inc.: financial statements, quarterly

GLXZ · OTC · CIK 13156 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/glxz.md) · [Financials](/companies/glxz/financials.md) · [Filings](/companies/glxz/filings.md) · [Insiders](/companies/glxz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/glxz/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [6,104](/filings/0000950170-24-124326.md) | [6,737 d](/filings/0000950170-25-043370.md) | [8,001](/filings/0000950170-25-068307.md) | [8,523](/filings/0000950170-25-106037.md) | [7,646](/filings/0001193125-25-272617.md) | [7,568 d](/filings/0001193125-26-129503.md) | [7,785](/filings/0001193125-26-215114.md) | [7,528](/filings/0001193125-26-340606.md) | [7,325](/filings/0001193125-25-272617.md) | [8,236 d](/filings/0001193125-26-129503.md) | [7,663](/filings/0001193125-26-215114.md) | [7,938](/filings/0001193125-26-340606.md) |
| Cost of revenue | $k | [188](/filings/0000950170-24-124326.md) | [224 d](/filings/0000950170-25-043370.md) | [406](/filings/0000950170-25-068307.md) | [599](/filings/0000950170-25-106037.md) | [343](/filings/0001193125-25-272617.md) | [162 d](/filings/0001193125-26-129503.md) | [188](/filings/0001193125-26-215114.md) | [188](/filings/0001193125-26-340606.md) | [241](/filings/0001193125-25-272617.md) | [163 d](/filings/0001193125-26-129503.md) | [67.2](/filings/0001193125-26-215114.md) | [82.0](/filings/0001193125-26-340606.md) |
| Research and development | $k | [226](/filings/0000950170-24-124326.md) | [190 d](/filings/0000950170-25-043370.md) | [252](/filings/0000950170-25-068307.md) | [269](/filings/0000950170-25-106037.md) | [261](/filings/0001193125-25-272617.md) | [274 d](/filings/0001193125-26-129503.md) | [363](/filings/0001193125-26-215114.md) | [243](/filings/0001193125-26-340606.md) | [231](/filings/0001193125-25-272617.md) | [94.8 d](/filings/0001193125-26-129503.md) | [152](/filings/0001193125-26-215114.md) | [129](/filings/0001193125-26-340606.md) |
| Selling, general and administrative | $k | [4,186](/filings/0000950170-24-124326.md) | [4,072 d](/filings/0000950170-25-043370.md) | [4,205](/filings/0000950170-25-068307.md) | [4,414](/filings/0000950170-25-106037.md) | [6,260](/filings/0001193125-25-272617.md) | [4,807 d](/filings/0001193125-26-129503.md) | [4,313](/filings/0001193125-26-215114.md) | [4,213](/filings/0001193125-26-340606.md) | [4,021](/filings/0001193125-25-272617.md) | [4,685 d](/filings/0001193125-26-129503.md) | [4,347](/filings/0001193125-26-215114.md) | [4,853](/filings/0001193125-26-340606.md) |
| Operating income | $k | [710](/filings/0000950170-24-124326.md) | [1,310 d](/filings/0000950170-25-043370.md) | [2,311](/filings/0000950170-25-068307.md) | [2,344](/filings/0000950170-25-106037.md) | [(124)](/filings/0001193125-25-272617.md) | [1,171 d](/filings/0001193125-26-129503.md) | [1,975](/filings/0001193125-26-215114.md) | [1,944](/filings/0001193125-26-340606.md) | [1,904](/filings/0001193125-25-272617.md) | [2,357 d](/filings/0001193125-26-129503.md) | [2,174](/filings/0001193125-26-215114.md) | [1,900](/filings/0001193125-26-340606.md) |
| Interest expense | $k | [2,302](/filings/0000950170-23-062659.md) | [2,316 d](/filings/0000950170-24-035514.md) | [2,289](/filings/0000950170-24-057992.md) | [2,281](/filings/0000950170-24-094921.md) | [2,293](/filings/0001193125-25-272617.md) | [2,203 d](/filings/0001193125-26-129503.md) | [1,003](/filings/0001193125-26-215114.md) | [907](/filings/0001193125-26-340606.md) | [872](/filings/0001193125-25-272617.md) | [806 d](/filings/0001193125-26-129503.md) | [776](/filings/0001193125-26-215114.md) | [813](/filings/0001193125-26-340606.md) |
| Income tax | $k | [41.6](/filings/0000950170-24-124326.md) | [15.3 d](/filings/0000950170-25-043370.md) | [26.3](/filings/0000950170-25-068307.md) | [28.3](/filings/0000950170-25-106037.md) | [7.2](/filings/0001193125-25-272617.md) | [(4.2) d](/filings/0001193125-26-129503.md) | [36.4](/filings/0001193125-26-215114.md) | [93.9](/filings/0001193125-26-340606.md) | [(24.0)](/filings/0001193125-25-272617.md) | [38.0 d](/filings/0001193125-26-129503.md) | [30.6](/filings/0001193125-26-215114.md) | [64.3](/filings/0001193125-26-340606.md) |
| Net income | $k | [(1,455)](/filings/0000950170-24-124326.md) | [(820) d](/filings/0000950170-25-043370.md) | [209](/filings/0001193125-25-272617.md) | [243](/filings/0001193125-25-272617.md) | [(2,198)](/filings/0001193125-25-272617.md) | [(881) d](/filings/0001193125-26-129503.md) | [(2,021)](/filings/0001193125-26-340606.md) | [950](/filings/0001193125-26-340606.md) | [1,039](/filings/0001193125-25-272617.md) | [1,515 d](/filings/0001193125-26-129503.md) | [1,368](/filings/0001193125-26-340606.md) | [997](/filings/0001193125-26-340606.md) |
| Diluted EPS | $ per share | [(0.06)](/filings/0000950170-24-124326.md) | not reported | [0.01](/filings/0000950170-25-068307.md) | [0.01](/filings/0000950170-25-106037.md) | [(0.09)](/filings/0001193125-25-272617.md) | not reported | [(0.08)](/filings/0001193125-26-215114.md) | [0.04](/filings/0001193125-26-340606.md) | [0.04](/filings/0001193125-25-272617.md) | not reported | [0.05](/filings/0001193125-26-215114.md) | [0.04](/filings/0001193125-26-340606.md) |
| Basic EPS | $ per share | [(0.06)](/filings/0000950170-24-124326.md) | not reported | [0.01](/filings/0000950170-25-068307.md) | [0.01](/filings/0000950170-25-106037.md) | [(0.09)](/filings/0001193125-25-272617.md) | not reported | [(0.08)](/filings/0001193125-26-215114.md) | [0.04](/filings/0001193125-26-340606.md) | [0.04](/filings/0001193125-25-272617.md) | not reported | [0.05](/filings/0001193125-26-215114.md) | [0.04](/filings/0001193125-26-340606.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [15.9](/filings/0000950170-23-062659.md) | [16.7](/filings/0000950170-25-043370.md) | [17.5](/filings/0000950170-24-057992.md) | [19.3](/filings/0000950170-24-094921.md) | [17.9](/filings/0000950170-24-124326.md) | [18.1](/filings/0001193125-26-129503.md) | [5.3](/filings/0000950170-25-068307.md) | [5.0](/filings/0000950170-25-106037.md) | [3.3](/filings/0001193125-25-272617.md) | [4.3](/filings/0001193125-26-340606.md) | [4.9](/filings/0001193125-26-215114.md) | [4.8](/filings/0001193125-26-340606.md) |
| Current assets | $m | [22.0](/filings/0000950170-23-062659.md) | [22.2](/filings/0000950170-25-043370.md) | [22.6](/filings/0000950170-24-057992.md) | [24.0](/filings/0000950170-24-094921.md) | [24.8](/filings/0000950170-24-124326.md) | [24.2](/filings/0001193125-26-129503.md) | [11.7](/filings/0000950170-25-068307.md) | [10.5](/filings/0000950170-25-106037.md) | [10.1](/filings/0001193125-25-272617.md) | [11.6](/filings/0001193125-26-340606.md) | [10.9](/filings/0001193125-26-215114.md) | [10.8](/filings/0001193125-26-340606.md) |
| Total assets | $m | [39.3](/filings/0000950170-23-062659.md) | [40.5](/filings/0000950170-25-043370.md) | [40.5](/filings/0000950170-24-057992.md) | [41.5](/filings/0000950170-24-094921.md) | [42.0](/filings/0000950170-24-124326.md) | [41.0](/filings/0001193125-26-129503.md) | [27.8](/filings/0000950170-25-068307.md) | [26.6](/filings/0000950170-25-106037.md) | [26.4](/filings/0001193125-25-272617.md) | [27.5](/filings/0001193125-26-340606.md) | [27.0](/filings/0001193125-26-215114.md) | [27.0](/filings/0001193125-26-340606.md) |
| Current liabilities | $m | [3.7](/filings/0000950170-23-062659.md) | [4.9](/filings/0000950170-25-043370.md) | [4.4](/filings/0000950170-24-057992.md) | [4.8](/filings/0000950170-24-094921.md) | [7.1](/filings/0000950170-24-124326.md) | [6.6](/filings/0001193125-26-129503.md) | [7.6](/filings/0000950170-25-068307.md) | [7.5](/filings/0000950170-25-106037.md) | [7.9](/filings/0001193125-25-272617.md) | [8.1](/filings/0001193125-26-340606.md) | [7.3](/filings/0001193125-26-215114.md) | [7.0](/filings/0001193125-26-340606.md) |
| Total liabilities | $m | [57.4](/filings/0000950170-23-062659.md) | [58.7](/filings/0000950170-25-043370.md) | [58.4](/filings/0000950170-24-057992.md) | [59.0](/filings/0000950170-24-094921.md) | [61.3](/filings/0000950170-24-124326.md) | [61.1](/filings/0001193125-26-129503.md) | [49.4](/filings/0000950170-25-068307.md) | [46.9](/filings/0000950170-25-106037.md) | [45.5](/filings/0001193125-25-272617.md) | [45.0](/filings/0001193125-26-340606.md) | [43.2](/filings/0001193125-26-215114.md) | [42.1](/filings/0001193125-26-340606.md) |
| Long-term debt | $m | [53.0](/filings/0000950170-23-062659.md) | [53.2](/filings/0000950170-25-043370.md) | [53.4](/filings/0000950170-24-057992.md) | [53.7](/filings/0000950170-24-094921.md) | [53.9](/filings/0000950170-24-124326.md) | [54.1](/filings/0001193125-26-129503.md) | [41.6](/filings/0000950170-25-068307.md) | [39.1](/filings/0000950170-25-106037.md) | [37.4](/filings/0001193125-25-272617.md) | [36.9](/filings/0001193125-26-340606.md) | [35.8](/filings/0001193125-26-215114.md) | [35.1](/filings/0001193125-26-340606.md) |
| Current portion of debt | $m | [0.9](/filings/0000950170-23-062659.md) | [0.9](/filings/0000950170-25-043370.md) | [0.8](/filings/0000950170-24-057992.md) | [0.7](/filings/0000950170-24-094921.md) | [0.9](/filings/0000950170-24-124326.md) | [0.8](/filings/0001193125-26-129503.md) | [2.4](/filings/0000950170-25-068307.md) | [2.3](/filings/0000950170-25-106037.md) | [2.5](/filings/0001193125-25-272617.md) | [2.4](/filings/0001193125-26-340606.md) | [2.6](/filings/0001193125-26-215114.md) | [2.8](/filings/0001193125-26-340606.md) |
| Shareholders' equity | $m | [(18.1)](/filings/0000950170-24-124326.md) | [(18.2)](/filings/0001193125-26-129503.md) | [(17.9)](/filings/0001193125-25-272617.md) | [(17.5)](/filings/0001193125-25-272617.md) | [(19.4)](/filings/0001193125-25-272617.md) | [(20.1)](/filings/0001193125-26-340606.md) | [(21.6)](/filings/0001193125-26-340606.md) | [(20.3)](/filings/0001193125-26-340606.md) | [(19.1)](/filings/0001193125-25-272617.md) | [(17.5)](/filings/0001193125-26-340606.md) | [(16.2)](/filings/0001193125-26-340606.md) | [(15.2)](/filings/0001193125-26-340606.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,095) d](/filings/0000950170-24-124326.md) | [2,330 d](/filings/0000950170-25-043370.md) | [1,367](/filings/0000950170-25-068307.md) | [2,507 d](/filings/0000950170-25-106037.md) | [(846) d](/filings/0001193125-25-272617.md) | [1,071 d](/filings/0001193125-26-129503.md) | [1,169](/filings/0001193125-26-215114.md) | [3,177 d](/filings/0001193125-26-340606.md) | [1,124 d](/filings/0001193125-25-272617.md) | [2,228 d](/filings/0001193125-26-129503.md) | [2,544](/filings/0001193125-26-215114.md) | [1,623 d](/filings/0001193125-26-340606.md) |
| Capital expenditure | $k | [0.0 d](/filings/0000950170-24-124326.md) | [0.0 d](/filings/0000950170-25-043370.md) | not reported | not reported | not reported | not reported | [93.7](/filings/0001193125-26-215114.md) | [0.0 d](/filings/0001193125-26-340606.md) | [0.0 d](/filings/0001193125-25-272617.md) | [29.3 d](/filings/0001193125-26-129503.md) | [63.8](/filings/0001193125-26-215114.md) | [11.9 d](/filings/0001193125-26-340606.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.9](/filings/0000950170-23-062659.md) | [25.4](/filings/0000950170-24-057992.md) | [25.5](/filings/0000950170-24-094921.md) | [24.5](/filings/0000950170-24-124326.md) | [24.9](/filings/0000950170-25-068307.md) | [25.7](/filings/0000950170-25-106037.md) | [25.7](/filings/0001193125-25-272617.md) | [25.9](/filings/0001193125-26-215114.md) | [26.2](/filings/0001193125-26-340606.md) | [26.3](/filings/0001193125-25-272617.md) | [26.2](/filings/0001193125-26-215114.md) | [26.1](/filings/0001193125-26-340606.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 25,023,865 at 2026-07-31, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-340606.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:17 ET. No prices; not investment advice.